<ol class="cite-this-references"><li id="reference-A725">Malhotra S, Shafiq N, Pandhi P: COX-2 inhibitors: a CLASS act or Just VIGORously promoted. MedGenMed. 2004 Mar 23;6(1):6. [<a href="/articles/A725" target="_blank">Article</a>] </li><li id="reference-A726">Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000 Sep 13;284(10):1247-55. [<a href="/articles/A726" target="_blank">Article</a>] </li><li id="reference-A727">Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005 Mar 17;352(11):1071-80. Epub 2005 Feb 15. [<a href="/articles/A727" target="_blank">Article</a>] </li><li id="reference-A728">Yelland MJ, Nikles CJ, McNairn N, Del Mar CB, Schluter PJ, Brown RM: Celecoxib compared with sustained-release paracetamol for osteoarthritis: a series of n-of-1 trials. Rheumatology (Oxford). 2007 Jan;46(1):135-40. Epub 2006 Jun 15. [<a href="/articles/A728" target="_blank">Article</a>] </li><li id="reference-A729">Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET: Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006 Aug 31;355(9):873-84. [<a href="/articles/A729" target="_blank">Article</a>] </li><li id="reference-A730">Sandberg M, Yasar U, Stromberg P, Hoog JO, Eliasson E: Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. Br J Clin Pharmacol. 2002 Oct;54(4):423-9. [<a href="/articles/A730" target="_blank">Article</a>] </li><li id="reference-A34124">Gong L, Thorn CF, Bertagnolli MM, Grosser T, Altman RB, Klein TE: Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012 Apr;22(4):310-8. doi: 10.1097/FPC.0b013e32834f94cb. [<a href="/articles/A34124" target="_blank">Article</a>] </li><li id="reference-A34152">Hawkey CJ: COX-1 and COX-2 inhibitors. Best Pract Res Clin Gastroenterol. 2001 Oct;15(5):801-20. doi: 10.1053/bega.2001.0236. [<a href="/articles/A34152" target="_blank">Article</a>] </li><li id="reference-A34171">Gwee KA, Goh V, Lima G, Setia S: Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: risks versus benefits. J Pain Res. 2018 Feb 14;11:361-374. doi: 10.2147/JPR.S156938. eCollection 2018. [<a href="/articles/A34171" target="_blank">Article</a>] </li><li id="reference-A34172">Chan FKL, Ching JYL, Tse YK, Lam K, Wong GLH, Ng SC, Lee V, Au KWL, Cheong PK, Suen BY, Chan H, Kee KM, Lo A, Wong VWS, Wu JCY, Kyaw MH: Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. Lancet. 2017 Jun 17;389(10087):2375-2382. doi: 10.1016/S0140-6736(17)30981-9. Epub 2017 Apr 11. [<a href="/articles/A34172" target="_blank">Article</a>] </li><li id="reference-A14814">Davies NM, McLachlan AJ, Day RO, Williams KM: Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2000 Mar;38(3):225-42. doi: 10.2165/00003088-200038030-00003. [<a href="/articles/A14814" target="_blank">Article</a>] </li><li id="reference-A4983">Ahmad SR, Kortepeter C, Brinker A, Chen M, Beitz J: Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf. 2002;25(7):537-44. doi: 10.2165/00002018-200225070-00007. [<a href="/articles/A4983" target="_blank">Article</a>] </li><li id="reference-A181526">Daniels S, Robbins J, West CR, Nemeth MA: Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies. Clin Ther. 2009 Jun;31(6):1192-208. doi: 10.1016/j.clinthera.2009.06.003. [<a href="/articles/A181526" target="_blank">Article</a>] </li><li id="reference-A181529">Frampton JE, Keating GM: Celecoxib: a review of its use in the management of arthritis and acute pain. Drugs. 2007;67(16):2433-72. doi: 10.2165/00003495-200767160-00008. [<a href="/articles/A181529" target="_blank">Article</a>] </li><li id="reference-A181532">Chen QW, Zhang XM, Zhou JN, Zhou X, Ma GJ, Zhu M, Zhang YY, Yu J, Feng JF, Chen SQ: Analysis of Small Fragment Deletions of the APC gene in Chinese Patients with Familial Adenomatous Polyposis, a Precancerous Condition. Asian Pac J Cancer Prev. 2015;16(12):4915-20. doi: 10.7314/apjcp.2015.16.12.4915. [<a href="/articles/A181532" target="_blank">Article</a>] </li><li id="reference-A181544">Shin S: Safety of celecoxib versus traditional nonsteroidal anti-inflammatory drugs in older patients with arthritis. J Pain Res. 2018 Dec 14;11:3211-3219. doi: 10.2147/JPR.S186000. eCollection 2018. [<a href="/articles/A181544" target="_blank">Article</a>] </li><li id="reference-A11861">Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, Shiau CW, Shaw YJ, Kulp SK, Chen CS: From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res. 2004 Jun 15;64(12):4309-18. doi: 10.1158/0008-5472.CAN-03-4063. [<a href="/articles/A11861" target="_blank">Article</a>] </li><li id="reference-A28426">Weber A, Casini A, Heine A, Kuhn D, Supuran CT, Scozzafava A, Klebe G: Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem. 2004 Jan 29;47(3):550-7. [<a href="/articles/A28426" target="_blank">Article</a>] </li><li id="reference-A20066">Nishimori I, Minakuchi T, Onishi S, Vullo D, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg Med Chem. 2007 Dec 1;15(23):7229-36. Epub 2007 Aug 25. [<a href="/articles/A20066" target="_blank">Article</a>] </li><li id="reference-A38563">Daily EB, Aquilante CL: Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009 Sep;10(9):1489-510. doi: 10.2217/pgs.09.82. [<a href="/articles/A38563" target="_blank">Article</a>] </li><li id="reference-A181379">Siu YA, Hao MH, Dixit V, Lai WG: Celecoxib is a substrate of CYP2D6: Impact on celecoxib metabolism in individuals with CYP2C9*3 variants. Drug Metab Pharmacokinet. 2018 Oct;33(5):219-227. doi: 10.1016/j.dmpk.2018.06.001. Epub 2018 Jun 19. [<a href="/articles/A181379" target="_blank">Article</a>] </li><li id="reference-T647">Brandon Cohen; Charles V. Preuss (2019). Celecoxib, NIH StatPearls. StatPearls. </li><li id="reference-L3293">FDA drug safety, June 28 2018 [<a href="https://www.fda.gov/Drugs/DrugSafety/ucm611959.htm" target="_blank">Link</a>] </li><li id="reference-L3294">Medscape drug reference [<a href="https://www.medscape.com/viewarticle/895722" target="_blank">Link</a>] </li><li id="reference-L3296">Pfizer Medical Information [<a href="https://www.pfizermedicalinformation.ca/en-ca/celebrex/action-and-clinical-pharmacology" target="_blank">Link</a>] </li><li id="reference-L7592">Medicines UK, Celebrex 200mg capsule [<a href="https://www.medicines.org.uk/emc/product/2945/smpc" target="_blank">Link</a>] </li><li id="reference-L7604">FDA approvals, Celebrex [<a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=020998" target="_blank">Link</a>] </li><li id="reference-L7607">Bpac NZ: Celecoxib [<a href="https://bpac.org.nz/2018/celecoxib.aspx" target="_blank">Link</a>] </li><li id="reference-L7610">CaymanChem: Celecoxib MSDS [<a href="https://www.caymanchem.com/msdss/10008672m.pdf" target="_blank">Link</a>] </li><li id="reference-L7622">US Pharmacist: Cardiovascular risk associated with NSAIDS and COX2 inhibitors [<a href="https://www.uspharmacist.com/article/cardiovascular-risk-associated-with-nsaids-and-cox2-inhibitors" target="_blank">Link</a>] </li><li id="reference-L7646">FDA Approved Drug Products: CELEBREX (celecoxib) oral capsules [<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020998s056lbl.pdf" target="_blank">Link</a>] </li><li id="reference-L35930">FDA Approved Drug Products: ELYXYB (celecoxib) solution [<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212157s002lbl.pdf" target="_blank">Link</a>] </li><li id="reference-L38949">FDA Approved Drug Products: SEGLENTIS (celecoxib and tramadol hydrochloride) tablets [<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213426s000lbl.pdf" target="_blank">Link</a>] </li></ol>